Join the conversation:
Investors
Investors

Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference

01/04/2012

SAN DIEGO, Jan. 4, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2012 at 2:00 p.m. PT / 5:00 p.m. ET. Greg I. Frost, Ph.D., president and chief executive officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. The Company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's ENHANZE™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition to partnerships that use Halozyme's ENHANZE™ Technology, the Company has a number of product candidates in its pipeline that target multiple areas of significant unmet medical need. For more information, visit www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com

 

SOURCE Halozyme

Delivering Value

We are developing and commercializing enzymes that modify tissue in the extracellular space. We are exploiting our unique scientific expertise by developing products for cancer, diabetes and dermatology. We also exploit this technology through partnerships.